Combating antimicrobial resistance in hospitals

Bibliography

• BRYCE EA, SMITH JA: Focused microbiological surveil-lance and gram-negative beta-lactamase-mediated re-sistance in an intensive care unit. Infect. Contr. Hosp. Epidemic)]. (1995) 16 (6) :331–334.
   PubMedGoogle Scholar
• GAYNES R: Antibiotic resistance in ICUs: a multifaceted problem requiring a multifaceted solution. Infect. Contr. Hosp. Epidemiol. (1995) 16(6):328–330.
   PubMedGoogle Scholar
• ARCHIBALD L, PHILLIPS L, MONNET D, MCGOWAN JE Jr., TENOVER FC, GAYNES RP: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin. Infect. Dis. (1997) 24:211–215.
   PubMed Web of Science ®Google Scholar
• TOMASZ A: Multiple-antibiotic-resistant pathogenic bacteria-a report on the Rockefeller University work-shop. New Engl. J. Med. (1994) 330(17):1247–1251.
   PubMed Web of Science ®Google Scholar
• ••Addresses the threat of antimicrobial resistance from a pub-lic health perspective.
   Google Scholar
• MCGOWAN JE Jr.: Antibiotic resistance in hospital bac-teria: current patterns, modes for appearance or spread, and economic impact. Rev. Med. Microbic)]. (1991) 2:161–169.
   Google Scholar
• HOLMBERG SD, SOLOMON SL, BLAKE PA: Health andeconomic impacts of antimicrobial resistance. Rev. In-fect. Dis. (1987) 9(6):1065–1078.
   PubMedGoogle Scholar
• US CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT:Impacts of antibiotic-resistant bacteria [OTA-H-629]. US Government Printing Office, Washington DC, USA (1995).
   Google Scholar
• ROMERO-VIVAS J, RUBIO M, FERNANDEZ C, PICAZO JJ:Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Infect. Dis. (1995) 21(6):1417–1423.
   PubMedGoogle Scholar
• EMORI TG, GAYNES RP: An overview of nosocomial in-fections, including the role of the microbiology labo-ratory. Clin. Microbiol. Rev. (1993) 6(4):428–442.
   PubMed Web of Science ®Google Scholar
• BREWER TF, HEYMANN SJ, ETTLING M: An effectiveness and cost analysis of presumptive treatment for Myco-bacterium tuberculosis. Am. J. Infect. Contr. (1998) 26(3):232–238.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL: Reduced susceptibil-ity of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46:624–626.
   PubMedGoogle Scholar
• ••Recommendations to prevent, detect and control S. aureuswith reduced susceptibility to vancomycin.
   Google Scholar
• VOSS A, MILATOVIC D, WALLRAUCH-SCHWARTZ C, ROS-DAHL VT, BRAVENY I: Methicillin-resistant Staphylo-coccus aureus in Europe. Eur. J. Gin. Microbiol. Infect. Dis. (1994) 13(0:50–55.
   PubMedGoogle Scholar
• HASHIMOTO H, INOUE M, HAYASHI I: A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jap. J. Antibiotics (1994) 47(6):618–623.
   PubMedGoogle Scholar
• HIRAMATSU K, HANAKI H, YABUTA K, OGURI T, TE-NOVER FC: Methicillin-resistant Staphylococcus au-reus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40(1):135–136.
   PubMed Web of Science ®Google Scholar
• •First report of a clinical strain of S. aureus with reduced van-comycin susceptibility.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Staphylococcus au-reus with reduced susceptibility to vancomycin-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(33)765–766.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Update: Staphylococ-cus aureus with reduced susceptibility to vancomycin-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(35):813–815.
   PubMedGoogle Scholar
• ROTUN SS, MCMATH V, SCHOONMAKER DJ et al.: Staphy-lococcus aureus with reduced susceptibility to vanco-mycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. (In Preparation). Also available at http://www.cdc.gov/ncidod/EID/eid.htm.
   Google Scholar
• SMITH TL, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin resistance in Staphylococcus aureus: epidemiology and clinical significance. New Engl. J. Med. (In Preparation).
   Google Scholar
• ••Review of clinical infections caused by S. aureus with re-duced vancomycin susceptibility.
   Google Scholar
• HIRAMATSU K, ARITAKA N, HIDEAKI H et al: Dissemina-tion in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lan-cet (1997) 350(9092):1670–1673.
   PubMedGoogle Scholar
• HOWE RA, BOWKER KE, WALSH TR, FEEST TG, MAC GOWAN AP: Vancomycin-resistant Staphylococ-cus aureus. Lancet (1998) 351 (9102):602.
   PubMedGoogle Scholar
• BANERJEE SN, EMORI TG, CULVER DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System. Am. J. Med. (1991) 91 (3B):86S–89S.
   Google Scholar
• WENZEL RP, NETTLEMAN MD, JONES RN, PFALLER MA: Methicillin-resistant Staphylococcus aureus: implica-tions for the 1990s and effective control measures. Am. J. Med. (1991) 91 (Suppl. 3N:2215–2275.
   Google Scholar
• TENOVER FC: Novel and emerging mechanisms of anti-microbial resistance in nosocomial pathogens. Am. J. Med. (1991) 91 (Suppl. 3B):765–815.
   Google Scholar
• GARRETT DO, JOCHIMSEN E, MURFITT K et al.: The emer-gence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Contr. Hosp. Epide-miol. (In Preparation).
   Google Scholar
• SCHWALBE RS, STAPLETON JT, GILLIGAN PH: Emer-gence of vancomycin resistance in coagulase-negative staphylococci. New Engl. J. Med. (1987) 316(15):927–931.
   PubMed Web of Science ®Google Scholar
• VEACH LA, PFALLER MA, BARRETT M, KOONTZ FR, WEN-ZEL RP: Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J. Clin. Microbiol. (1990) 28(9)2064–2068.
   Google Scholar
• MURRAY BE: The life and the times of the Enterococcus. Clin. Microbiol. Rev. (1990) 3(0:46–65.
   PubMedGoogle Scholar
• WOODFORD N, JOHNSON AP, MORRISON D, SPELLER DC: Current perspectives on glycopeptide resistance. Microbiol. Rev. (1995) 8(4):585–615.
   Google Scholar
• ENA J, DICK RW, JONES RN, WENZEL RP: The epidemiol-ogy of intravenous vancomycin usage in a university hospital. JAMA (1993) 269 (5) :598–602.
   PubMedGoogle Scholar
• SHAY DK, MALONEY SA, MONTECALVO M et al.: Epide-miology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J. Infect. Dis. (1995) 172(4):993–1000.
   PubMed Web of Science ®Google Scholar
• MORRIS JG, SHAY DK, HEBDEN JN et al.: Enterococci re-sistant to multiple antimicrobial agents, including vancomycin. Establishment of endemnicity in a uni-versity medical center. Ann. Int. Med. (1995) 123(4):250–259.
   PubMed Web of Science ®Google Scholar
• HUYCKE MM, SAHM DF, GILMORE MS: Multiple-drug re-sistant enterococci: The nature of the problem and an agenda for the future. Emerg. Infect. Dis. (1998) 4(2):239–249.
   PubMed Web of Science ®Google Scholar
• •Review of VRE with recent data from The Surveillance Net-work (TSN)-USA.
   Google Scholar
• NOBEL WC, VIRANI Z, CREE RG: Co-transfer of vanco-mycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. (1992) 72:195–198.
   Google Scholar
• PIDDOCK LJ, WALTERS RN, JIN YF et al: Prevalence and mechanism of resistance to `third-generation' cepha-losporins in clinically relevant isolates of Enterobacte-riaceae from 43 hospitals in the UK, 1990-1991. J. Antimicrob. Chemother. (1997) 39(2):177–187.
   PubMedGoogle Scholar
• LIVERMORE DM, YUAN M: Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J. Antimicrob. Chemother. (1996) 38(3)409–424.
   Google Scholar
• NEUWIRTH C, SIEBOR E, LOPEZ J, PICHINOT A, KAZ-MIERCZAK A: Outbreak of TEM-24-producing Entero-barter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family Enterobacte-riaceae. Clin. Microbiol. (1996) 24(1):76–79.
   Google Scholar
• YUAN M, AUCKEN H, HALL LM, PITT TL, LIVERMORE DM:Epidemiological typing of Klebsiellae with extended-spectrum beta-lactamases from European intensive care units. J Antimicrob. Chemother. (1998) 41 (5):527–539.
   Google Scholar
• COHN DL, BUSTREO F, RAVIGLIONE MC: Drug-resistanttuberculosis: Review of the worldwide situation and the WHO/lUATED Global Surveillance Project. Clin. In-fect. Dis. (1997) 24 (Suppl. 1):S121–S130.
   Google Scholar
• •An overview of drug-resistant tuberculosis and the current global situation.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Nosocomial trans-mission of multidrug-resistant tuberculosis to health-care workers and HIV infected patients in an urban hospital-Florida. MMWR Morb. Mortal. Wkly. Rep. (1990) 39(40718–722.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Transmission of multidrug-resistant tuberculosis from an 'IN-positive client in a residential substance-abuse treatment facil-ity-Michigan. MMWR Morb. Mortal. Wkly. Rep. (1991) 40(0129–131.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL: Nosocomial trans-mission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb. Mortal. Wkly. Rep. (1991) 40(34):578–591.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Transmission of multi-drug resistant tuberculosis among immunocom-promised persons in a correctional system-New York, 1991. MMWR Morb. Mortal. Wkly. Rep. (1992) 41(28):507–509.
   PubMedGoogle Scholar
• KENYON TA, RIDZON R, LUSKIN-HAWK R et al.: A noso-comial outbreak of multidrug-resistant tuberculosis. Ann. InL Med. (1997) 127(1):32–36.
   PubMedGoogle Scholar
• FRIDKIN SK, WEBEL SF, WEINSTEIN RA: Magnitude andprevention of nosocomial infections in the intensive care unit. Infect. Dis. Clin. N Am. (1997) 11(2):479–496.
   PubMedGoogle Scholar
• PFALLER MA, HERWALDT LA: The clinical microbiologylaboratory and infection control: emerging patho-gens, antimicrobial resistance, and new technology. Clin. Infect. Dis. (1997) 25(4):858–870.
   PubMedGoogle Scholar
• •Defines the role of the clinical laboratory in detection and control of resistant organisms.
   Google Scholar
• GHANNOUM MA, REX JH, GALGIANI JN: Susceptibilitytesting of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol (1996) 34(3)489–495.
   Google Scholar
• ABI-SAID DAE, UZUN O, RAAD IPH, VARTIVARIAN S: Theepidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. (1997) 24(6):1129–1130.
   PubMedGoogle Scholar
• WINGARD JR: Infections due to resistant Candida spe-cies in patients with cancer who are receiving chemo-therapy. Clin. Infect. Dis. (1994) 19\(Suppl. 0:549–553.
   PubMedGoogle Scholar
• BARCHIESI F, HOLLIS RJ, DEL POETA M et al.: Transmis-sion of fluconazole-resistant Candida albicans be-tween patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electro-phoresis. Clin. Infect. Dis. (1995) 21 (3) :561–564.
   PubMedGoogle Scholar
• SPEERT DP: Antimicrobial resistance: implications for therapy of infections with common childhood patho-gens. Can. J. Infect. Dis. (1996) 7 (3) :169–173.
   PubMedGoogle Scholar
• COL NF, O'CONNER RW: Estimating the worldwide cur-rent antibiotic usage: report of Task Force 1. Rev. Infect. Dis. (1987) 9\(Suppl. 1):S232–5243.
   Google Scholar
• BAQUERO F: Antibiotic resistant in Spain: what can be done? Clin. Infect. Dis. (1996) 23(4) :819–823.
   PubMedGoogle Scholar
• •Reviews antibiotic consumption and the development of re-sistance in Spain.
   Google Scholar
• PHELPS CE: Bug/drug resistance. Sometimes less is more. Med. Care (1989) 27(2):194–203.
   PubMedGoogle Scholar
• HOLMBERG SD, OSTERHOLM MT, SENGER KA, COHEN ML: Drug-resistant salmonella from animals fed anti-microbials. New Engl. J. Med. (1984) 311 (10) :617–622.
   PubMed Web of Science ®Google Scholar
• LEVY SB, FITZGERALD GB, MACONE AM: Changes in in-testinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. New Engl. J. Med. (1976) 295(11):583–588.
   PubMed Web of Science ®Google Scholar
• LEVY SB: Multidrug resistance-a sign of the times. New Engl. J. Med. (1998) 338(101376–1378.
   Google Scholar
• GAYNES R: The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hos-pitals. Infect. Dis. Clin. N Am. (1997) 11(4):757–765.
   PubMed Web of Science ®Google Scholar
• ••Addresses the link between antibiotic use and resistance.
   Google Scholar
• MCGOWAN JE Jr.: Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev. Infect. Dis. (1983) 5(6):1033–1048.
   PubMedGoogle Scholar
• BALLOW CH, SCHENTAG JJ: Trends in antibiotic utiliza-tion and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn. Mi-crobiol. Infect. Dis. (1992) 15(2 Suppl):375–425.
   PubMedGoogle Scholar
• COURCOL RJ, PINKAS M, MARTIN GR: A seven-year sur-vey of antibiotic susceptibility and its relationship with usage. J. Antimicrob. Chemother. (1989) 23 (3):441–451.
   PubMedGoogle Scholar
• MONNET DL, ARCHIBALD LK, PHILLIPS L et al.: Antimi-crobial use and resistance in eight US hospitals: com-plexities of analysis and modelling. Infect. Contr. Hosp. Epidemiol (1998) 19(6):388–394.
   PubMed Web of Science ®Google Scholar
• RIDLEY M, LYNN R, BARRIE D, STEAD KC: Antibiotic-resistant Staphylococcus aureus and hospital antibi-otic policies. Lancet (1970) 1(7640):230–233.
   PubMedGoogle Scholar
• SHULMAN JA, TERRY PM, HOUGH CE: Colonization with gentamicin-resistant Pseudomonas aeruginosa, pyo-cine Type 5, in a burn unit. J. Infect. Dis. (1971) 124(Suppl.):S18–S22.
   Google Scholar
• COMMETTA A, CALANDRA T, BILLE J, GLAUSER MP: Escherichia colt resistant to fluoroquinolones in pa-tients with cancer and neutropenia. New Engl. J. Med. (1993) 330(17):1240–1241.
   Google Scholar
• SCHENTAG JJ, HYATT JM, CARR JR et al: Genesis ofmethicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin. Infect. Dis. (1998) 26(5):1204–1214.
   PubMedGoogle Scholar
• BOYCE JM, WHITE RL, CAUSEY WA, LOCKWOOD WR:Burn units as a source of methicillin-resistant Staphy-lococcus aureus infections. JAMA (1983) 249(20)2803–2807.
   Google Scholar
• EDMOND MB, OBER JF, WEINBAUM DL et al.: Vancomycin-resistant Enterococcus faecium bactere-mia: risk factors for infection. Clin. Infect. Dis. (1995) 20(5) :1126–1133.
   PubMed Web of Science ®Google Scholar
• PLESSIS P, LAMY T, DONNIO PY et al.: Epidemiologicanalysis of glycopeptide-resistant Enterococcus strains in neutropenic patients receiving prolonged vancomycin administration. Eur. J. Clin. Microbic)]. In-fect. Dis. (1995) 14(10:959–963.
   PubMedGoogle Scholar
• QUALE J, LANDMAN D, SAURINA G et al: Manipulationof a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Infect. Dis. (1996) 23(5):1020–1025.
   Google Scholar
• FLAHERTY JP, WEINSTEIN RA: Nosocomial infectioncaused by antibiotic-resistant organisms in the intensive-care unit. Infect. Contr. Hosp. Epidemic)]. (1996) 17(4)236–248.
   Google Scholar
• GREENWOOD D: Tarnished gold: sixty years of antimi-crobial drug use and misuse. J. Med. Microbiol. (1995) 43 (6):395–396.
   PubMedGoogle Scholar
• MCGOWAN JE Jr., GERDING DN: Does antibiotic restric-tion prevent resistance? New Horizons (1996) 4(3)370–376.
   PubMedGoogle Scholar
• JARVIS WR: Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect. Contr. Hosp. Epidemic)]. (1996) 17(8):490–495.
   PubMedGoogle Scholar
• •Review of antimicrobial use controls in the healthcare setting.
   Google Scholar
• MCGOWAN JE Jr.: Do intensive hospital antibiotic con-trol programs prevent the spread of antibiotic resis-tance? Infect. Contr. Hosp. Epidemiol. (1994) 15 (7):478–483.
   PubMedGoogle Scholar
• www.who.int/emc/diseases/zoo/zoo97_4.html The medical impact of the use of antimicrobials in food animals. In: Report of a WHO Meeting in Berlin, Ger-many 13–17 October 1997 World Health Organisation, Ge-neva (1997).
   Google Scholar
• •Outlines the problem with antibiotic use in animal hus-bandry and gives recommendations for control.
   Google Scholar
• MCGOWAN JE Jr., TENOVER FC: Control of antimicro-bial resistance in the health care system. Infect. Dis. Clin. N Am. (1997) 11(2):297–311.
   PubMedGoogle Scholar
• MARR JJ, MOFFAT HL, KUNIN CM: Guidelines for im-proving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of Amer-ica. J. Infect. Dis. (1988) 157(5):869–876.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL: Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practice Advisory Committee (HICPAC). MMWR Morb. Mortal. Wkly. Rep. (1995) 44 (RR-12) :1–13.
   PubMedGoogle Scholar
• •Recommendations for controlling the spread of vancomycin resistance in the healthcare setting.
   Google Scholar
• SHLAES DM, GERDING DN, JOHN JF et al.: SHEA IDSAjoint committee on the prevention of antimicrobial re-sistance: Guidelines for the prevention of antimicro-bial resistance in hospitals. Clin. Infect. Dis. (1997) 25 (3):584–599.
   PubMed Web of Science ®Google Scholar
• GOLDMANN DA, WEINSTEIN RA, WENZEL RP et al: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA (1996) 275(3)234–240.
   PubMedGoogle Scholar
• KRITCHEVKY SB, SIMMONS BP: Toward better antibiotic use in hospitals. Infect. Contr. Hosp. Epidemiol. (1994) 15(10688–690.
   Google Scholar
• KOSECOFF J, CHASSIN MR, FINK A et al.: Effects of the Na-tional Institutes of Health Consensus Development Program on physician practice. JAMA (1987) 258(19)2538–2542.
   PubMedGoogle Scholar
• PICHETTE SC: Clinical practice guidelines in patients' charts may decrease vancomycin use. Cause (1998) 2(2):3.
   Google Scholar
• RECCO RA, GLADSTONE JL, FRIEDMAN SA, GERKEN EH: Antibiotic control in a municipal hospital. JAMA (1979) 241(202283–2286.
   Google Scholar
• MCGOWAN JE Jr., FINLAND M: Effects of monitoring the usage of antibiotics: an interhospital comparison. South Med. J. (1976) 69(2):193–195.
   PubMedGoogle Scholar
• KLEM C, DASTA JF: Efforts of pharmacy to reduce anti-biotic resistance. New Horizons (1996) 4 (3):377–384.
   PubMedGoogle Scholar
• MCGOWAN JE Jr.: Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect. Contr. (1986) 7(12):573–576.
   PubMedGoogle Scholar
• •Describes novel approaches for improving rational antibi-otic use.
   Google Scholar
• BONHOEFFER S, LIPSITCH M, LEVIN BR: Evaluating treat-ment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA (1997) 94(22):12106–12111.
   PubMed Web of Science ®Google Scholar
• •Proposes criteria for evaluating the population-wide effects of treatment protocols.
   Google Scholar
• DUA V, KUNNIN CM, WHITE LV: The use of antimicro-bial drugs in Nagpur, India. A window on medical care in a developing country. Social Sci. & Med. (1994) 38 (5):717–724.
   PubMedGoogle Scholar
• BOJALIL R, CALVA JJ, ORTEGA H: The use of antibiotics in a community of Mexico City. I. A household survey. Boletin Medico del Hosptial Infantil de Mexico (1993) 50(2):79–87.
   PubMedGoogle Scholar
• ADU-SARKODIE YA: Antimicrobial self medication inpatients attending a sexually transmitted diseases clinic. Internad. J. STD & AIDS (1997) 8(7):456–458.
   PubMedGoogle Scholar
• LEVY SB: Antibiotic resistance worldwide-a Spanishtask force responds. Clin. Infect. Dis. (1996) 23(4)824–826.
   PubMedGoogle Scholar
• MAHMOUDI A, ISEMAN MD: Pitfalls in the care of pa-tients with tuberculosis: common errors and their as-sociation with the acquisition of drug resistance. JAMA (1993) 270(0:65–68.
   PubMedGoogle Scholar
• ISEMAN MD, MADSEN L, GOBLE M, POMERANTZ M: Sur-gical intervention in the treatment of pulmonary dis-ease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Resp. Dis. (1990) 141(3):623–625.
   PubMed Web of Science ®Google Scholar
• WETS SE, SLOCUM PC, BLAIS FX et al: The effect of di-rectly observed therapy on the rates of drug resistance and relapse in tuberculosis. New Engl. J. Med. (1994) 330(17):1179–1184.
   PubMedGoogle Scholar
• JOHNSON MW, MITCH WE, HELLER AH, SPECTOR R: Theimpact of an educational program on gentamicin use in a teaching hospital. Am. J. Med. (1982) 73(1):9–14.
   PubMedGoogle Scholar
• GILBERT DN, EUBANKS NM, JACKSON JM: The effects ofmonitoring the use of gentamicin in a community hos-pital. J Med. Educat (1978) 53(2):129–134.
   Google Scholar
• JONES SR, PANNELL J, BARKS J et al.: The effect of an edu-cational program upon hospital antibiotic use. Am. J. Med. Sci. (1977) 273(0:79–85.
   PubMedGoogle Scholar
• SCHROEDER SA, MYERS LP, MCPHEE SJ et al. The failure of physician education as a cost containment strategy. Report of a prospective controlled trial at a university hospital. JAMA (1984) 252(2)225–230.
   PubMedGoogle Scholar
• AVORN J, HARVEY K, SOUMERAI SB et al: Information and education as determinants of antibiotic use: re-ports of Task Force 5. Rev. Infect. Dis. (1987) 9\(Suppl. 3):S286–S296.
   Google Scholar
• SOUMERAI SB: Quality assurance for drug prescribing. Qual. Assur. Healthcare (1990) 2(0:37–58.
   Google Scholar
• WILLIAMS RR, GROSS PA, LEVINE JF: Cost containment of the second-generation cephalosporins by prospec-tive monitoring at a community teaching hospital. Arch. Int. Med. (1985) 145(10:1978–1981.
   PubMedGoogle Scholar
• BANERJEE A, SALANIPONI F, HARRIES A: Administration of anti-tuberculosis drugs through patient empower-ment. Trop. Doctor (1997) 27(4):240.
   PubMedGoogle Scholar
• MORRIS LA, HALPERN JA: Effects of written drug infor-mation on patient knowledge and compliance: a litera-ture review. Am. J. Public Health (1979) 69 (0 :47–52.
   PubMedGoogle Scholar
• KESSLER RE: Perspectives on chemotherapeutic ap-proaches to antibiotic-resistant bacteria. Clin. Infect. Dis. (1997) 24\(Suppl. 0:5146–5147.
   Google Scholar
• ••Proposes novel therapeutic approaches to resistantorganisms.
   Google Scholar
• BAX RP: Antibiotic resistance: a view from the pharma-ceutical industry. Clin. Infect. Dis. (1997) 24 (Suppl 1):S151–S153.
   PubMedGoogle Scholar
• •An industry perspective on approaches to addressing resistance.
   Google Scholar
• MURRAY BE: Can antibiotic resistance be controlled? New Engl. J. Med. (1994) 330(17):1229–1230.
   PubMed Web of Science ®Google Scholar
• •Emphasises the role of infection control in limiting the spread of resistant organisms.
   Google Scholar
• BILLSTEIN SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Anti-microb. Agents Chemother. (1994) 38(12):2679–2682.
   PubMedGoogle Scholar
• HALEY RW, CUSHION NB, TENOVER FC: Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J. Infect. Dis. (1995) 171(3):614–624.
   PubMedGoogle Scholar
• STARLING CE, COUTO BR, PINHEIRO SM: Applying the Centers for Disease Control and Prevention and Na-tional Nosocomial Surveillance system methods in Brazilian hospitals. Am. J. Infect. Contr. (1997) 25(4)303–311.
   PubMedGoogle Scholar
• JOCHIMSEN EM, FISH L, MANNING K et al. Control of vancomycin-resistant Enterococci at a community hospital. Infect. Contr. Hosp. Epidemiol. (In Preparation).
   Google Scholar
• MONTECALVO MA, UMAN J, PETRULLO C et al.: The cost-benefit of Enhanced Infection Control Strategies (EICS) to prevent transmission of vancomycin-resistant enterococci (VRE). 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Can-ada. (1997) J–84.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Guidelines for Pre-venting the Transmission of Mycobacterium tubercu-losis in Health-Care Facilities, 1994. MMWR Morb. Mortal. Wkly. Rep. (1994) 44 (RR-13):1–132.
   Google Scholar
• MALONEY SA, PEARSON ML, GORDON MT et al.: Efficacy of control measures in preventing nosocomial trans-mission of multidrug-resistant tuberculosis to patients and health care workers. Ann. Int. Med. (1998) 122(2)90–95.
   Google Scholar
• WENGER PN, OTTEN J, BREEDEN A et al.: Control of no-socomial transmission of multidrug-resistant Myco-bacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet (1995) 345(8944):235–240.
   PubMedGoogle Scholar
• JARVIS WR: Handwashing -the Semmelweis lesson for-gotten? Lancet (1994) 344(8933):1311–1312.
   PubMedGoogle Scholar
• ALBERT RK, CONDIE F: Hand-washing practices in medical intensive-care units. New Engl. J. Med. (1981) 304(24)1465–1466.
   PubMedGoogle Scholar
• GRAHAM M: Frequency and duration of handwashing in an intensive care unit. Am. J. Infect. Contr. (1990) 18 (2):77–81.
   PubMedGoogle Scholar
• ZIMAKOFF J, STORMARK M, LARSEN SO: Use of gloves and handwashing behaviour among health care work-ers in intensive care units. A multicentre investigation in four hospitals in Denmark and Norway. J. Hosp. In-fect. (1993) 24(0:63–67.
   PubMedGoogle Scholar
• DOEBBLING BN, STANLEY GL, SHEETZ CT: Comparative efficacy of alternative hand-washing agents in reduc-ing nosocomial infections in intensive care units. New Eng]. J. Med. (1992) 327(2):88–93.
   PubMedGoogle Scholar
• LARSON EL, BRYAN JL, ADLER LM, BLANE C: A multifac-eted approach to changing handwashing behaviour. Am. J. Infect. Contr. (1997) 25(0:3–10.
   PubMedGoogle Scholar
• •Approaches to improve handwashing compliance in health-care workers.
   Google Scholar
• SPROAT LJ, INGLIS TJ: A multicentre survey of hand hy-giene practice in intensive care units. J. Hosp. Infect. (1994) 26(2):137–148.
   PubMedGoogle Scholar
• DONOWITZ LG: Handwashing technique in a pediatric intensive care unit. Am. J. Dis. Children (1987) 141 (6):683–685.
   PubMedGoogle Scholar
• DUBBERT PM, DOLCE J, RICHTER W, MILLER M, CHAP-MAN SW: Increasing ICU staff handwashing: effects of education and group feedback. Infect. Contr. Hosp. Epi-demiol. (1990) 11(4):191–193.
   PubMedGoogle Scholar
• LARSON E, MCGEER A, QURAISHI AZ: Effect of an auto-mated sink on handwashing practices and attitudes in high-risk units. Infect. Contr. Hosp. Epidemic]. (1991) 12(7)422–428.
   Google Scholar
• SIMMONS B, BRYANT J, NEIMAN K, SPENCER L, ARHEART K: The role of handwashing in prevention of endemic intensive care unit infections. Infect. Contr. Hosp. Epide-miol. (1990) 11(10:589–594.
   PubMedGoogle Scholar
• BISHOFF WE, REYNOLDS TM, SESSLER CN, EDMOND MB, WENZEL RP: Handwashing compliance by health care workers: the impact of an education and awareness program. 8th Annual Meeting of the Society for Healthcare Epidemiology. Orlando, Florida, USA (1998). 22.
   Google Scholar
• KRETZER EK, LARSON EL: Behavioral interventions to improve infection control practices. Am. J. Infect. Contr. (1998) 26(3):245–253.
   PubMed Web of Science ®Google Scholar
• GARNER JS, FAVERO MS: CDC guideline for handwash-ing and hospital environmental control, 1985. Infect. Contr. Hosp. Epidemic]. (1986) 7(4):231–243.
   Google Scholar
• GARNER JS, THE HOSPITAL INFECTION CONTROL PRAC-TICES COMMITTEE: Guideline for isolation precautions in hospitals. Infect. Contr. Hosp. Epidemiol. (1996) 17(1)53–80.
   PubMedGoogle Scholar
• JERNIGAN JA, CLEMENCE MA, STOTT GA: Control of methicillin-resistant Staphylococcus aureus at a uni-versity hospital: one decade later. Infect. Contr. Hosp. Epidemiol. (1995) 16(12):686–696.
   PubMedGoogle Scholar
• MOTECALVO MA, HORWITZ H, GEDRIS C et al.: Outbreak of vancomycin, ampicillin and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother. (1994) 38(6):1363–1367.
   PubMedGoogle Scholar
• WEINSTEIN RA: Epidemiology and control of noso-comial infections in adult intensive care units. Am. J. Med. (1991) 91(3B):1795–1845.
   Google Scholar
• WEINER J, ITOKAZU G, NATHAN C, KABINS SA, WEIN-STEIN RA: A randomized, double-blind placebo-controlled trial of selective digestive decontamination in a medical-surgical intensive care unit. Clin. Infect. Dis. (1995) 20(4):861–867.
   PubMedGoogle Scholar
• VERHOEF J, VERHAGE EA, VISSER MR: A decade of expe-rience with selective decontamination of the digestive tract as prophylaxis for infections in patients in the in-tensive care unit: what have we learned? Clin. Infect. Dis. (1993) 17(6):1047–1054.
   PubMedGoogle Scholar
• REAGAN DR, DOEBBLING BN, PFALLER MA et al.: Elimi-nation of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mu-piricin calcium ointment. Ann. Int. Merl. (1991) 114 (2):101–106.
   PubMed Web of Science ®Google Scholar
• www.who.int/whr/ 191996/whr-e.htm Executive summary: Fighting Disease, fostering devel-opment. In: The World Health Report 1996. World Health Organisation, Geneva (1996).
   Google Scholar
• INSTITUTE OF MEDICINE: Emerging infections: micro-bial threats to health in the United States. LEDERBERG J, SHOPE RE, OAKS SC (Eds.) National Academy Press, Wash-ington, D.C. (1992).
   Google Scholar
• ••Outlines the public health significance of antimicrobialresistance.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Addressing emerging infectious diseases threats: a prevention strategy for the United States executive summary. MMWR Morb. Mortal. Wkly. Rep. (1994) 43 (RR-5):1–18.
   Google Scholar
• SAHM DF, TENOVER FC: Surveillance for the emergence and dissemination of antimicrobial resistance in bac-teria. Infect. Dis. Clin. N Am. (1997) 11(4):767–783.
   PubMedGoogle Scholar
• ••Excellent review of surveillance for antimicrobial resistance.
   Google Scholar
• TOLLEFSON L: National antimicrobial resistance moni-toring program. Cause (1998) 2 (1) :2.
   Google Scholar
• PUTMAN L: Keeping global tabs on antimicrobial resis-tance. Lancet (1998) 351(9110:689.
   PubMedGoogle Scholar
• GROSS PA: The potential for clinical guidelines to im-pact appropriate antimicrobial agent use. Infect. Dis. Clin. IV. Am. (1997) 11(4):803–812.
   PubMedGoogle Scholar
• TENOVER FC, ARBEIT RD, GOERING RV: How to select and interpret molecular strain typing methods for epi-demiological studies of bacterial infections: a review for healthcare epidemiologists. Infect. Contr. Hosp. Epi-demic)]. (1997) 18(6):426–439.
   PubMedGoogle Scholar
• •Describes the role of molecular techniques in outbreak in-vestigation and surveillance.
   Google Scholar
• BECK-SAGUE C, JARVIS WR, MARTONE WJ: Outbreak in-vestigations. Infect. Contr. Hosp. Epidemiol. (1997) 18 (2) :138–45.
   PubMedGoogle Scholar
• COUPER MR: Strategies for the rational use of antimi-crobials. Clin. Infect. Dis. (1997) 24 (Suppl. 1):S154–S156.
   Google Scholar
• ••World Health Organisation strategies for improving antimi-crobial use.
   Google Scholar
• www.who.ch/whr/ 191998/reports.html Executive summary: Life in the 21st century-A vision for all. In: The World Health Report 1998. World Health Or-ganisation, Geneva (1998).
   Google Scholar
• Centers for Disease Control: Status report on childhood immunization initiative: reported cases of selected vaccine-preventable diseases-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(29):665–671.
   PubMedGoogle Scholar
• STYBLO K, MEIJER J: Impact of BCG vaccination pro-grammes in children and young adults on the tubercu-losis program. Tubercle (1976) 57(1):17–43.
   PubMedGoogle Scholar
• Centers for Disease Control: Development of new vac-cines for tuberculosis. Recommendations of the Advi-sory Council for the Elimination of Tuberculosis. MMWR Morb. Mortal. Wkly. Rep. (1998) 47(RR-13):1–6.
   PubMedGoogle Scholar
• Centers for Disease Control: Preventing emerging infec-tious diseases threats: a strategy for the 21st century. Overview of the updated CDC plan. MMWR Morb. Mor-tal. Wkly. Rep. (1998) 47 (RR-15) :1–14.
   Google Scholar
• ••Emphasises the importance of resistance and strategies tocontrol its spread in the USA.
   Google Scholar
• WEINSTEIN RA: Nosocomial infection update. Em erg. In-fect. Dis. (1998) 4 (3) :416–420.
   PubMedGoogle Scholar
• ••Excellent review of emerging nosocomial infections.
   Google Scholar
• LEVY SB: Confronting multidrug resistance: a role for each of us. JAMA (1993) 269(14):1840–1842.
   PubMedGoogle Scholar